EUDA Health (EUDA) announced that it has signed a Letter of Intent, LOI, to potentially acquire Chemokine. EUDA will carry out due diligence on Chemokine, subject to confidentiality obligations. Chemokine has agreed to an exclusivity period of at least one hundred and twenty days during which it shall not engage in any discussions with any other entity relating to any transaction similar to this potential acquisition.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EUDA:
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- EUDA Health Secures Global Rights for New Immune Supplement
- EUDA Health Stock Pops 14% on New Wellness Deal
- EUDA Health secures worldwide distribution rights for Chemokine supplement
- EUDA Health Holdings Secures $10 Million Convertible Note Agreement